Valeo Pharma Inc said it completed its negotiations and entered into a letter of intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) regarding its two innovative asthma therapies, Enerzair Breezhaler and Atectura Breezhaler.
The pCPA conducts joint provincial, territorial and federal negotiations for brand name and generic drugs in Canada to achieve greater value for publicly funded drug programs and patients through the use of the combined negotiating power of participating jurisdictions.
Valeo said it can now work with participating jurisdictions to secure coverage from publicly funded drug plans across Canada. In addition, it noted that private payer health plan coverage currently stands in excess of 85% of privately insured lives in Canada.
READ: Valeo Pharma says Redesca is now covered for public reimbursement across much of Canada
"As expected, the feedback gathered by our commercial team from healthcare professionals since launching these two innovative asthma drugs is very positive,” Valeo president and chief operating officer Frederic Fasano said in a statement.
“The large phase III PLATINUM program is continuously delivering further endpoint analyses which are strengthening the clinical profile of both products.
“We are convinced that the clinical value propositions of Enerzair Breezhaler and Atectura Breezhaler will help expedite provincial public coverage to the benefits of asthma sufferers across Canada."
Enerzair Breezhaler is indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long-acting beta2-agonist and a medium or high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous 12 months.
Atectura Breezhaler is indicated as a once-daily maintenance treatment of asthma in adults and adolescents 12 years of age and older with reversible obstructive airways disease.
Valeo Pharma is a pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on respirology, neurodegenerative diseases, oncology and other specialty products.
Headquartered in Kirkland, Quebec, the company has the full capability and complete infrastructure to register and properly manage its growing product portfolio through all stages of commercialization.
Contact the author at stephen.gunnion@proactiveinvestors.com